How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of proactive chemistry, manufacturing, and controls strategies.
Louis Cicchini, PhD, and Michael Day, PhD
Advertisement
Articles by Louis Cicchini, PhD, and Michael Day, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
2
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
3
Pharmaceutical Executive Daily: Analysis on TrumpRx List Pricing
4
What is the Next Threat Manufacturers at Access USA Need to Be Preparing For?
5